We advised GSK on the transaction

Davis Polk advised GSK in connection with an exclusive license agreement with Hansoh Pharma. Under this agreement, Hansoh grants GSK an exclusive license for the development and commercialization of HS-20089 in all countries other than mainland China, Hong Kong, Macau and Taiwan. HS-20089 is an antibody-drug conjugate (ADC) that targets the B7-H4 surface antigen, which is overexpressed in ovarian and endometrial cancers. The transaction is expected to close in the fourth quarter of 2023, following satisfaction of customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

Hansoh is a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders.

The Davis Polk IP, tech and commercial transactions team included partner David R. Bauer, counsel Samantha Lefland and associates Yana Kipnis and Brette L. Trost. The tax team included partner William A. Curran and associate Ted Lee. The antitrust and competition team included partner Jesse Solomon, counsel Mary K. Marks and Matthew Yeowart and associate Tara Shah. Members of the Davis Polk team are based in the New York, Washington DC and London offices.

Copy link to share post